CRIS Current Research Information System

POLUZZI, ELISABETTA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 13.410
AS - Asia 13.291
EU - Europa 10.290
AF - Africa 817
SA - Sud America 752
OC - Oceania 46
Continente sconosciuto - Info sul continente non disponibili 7
Totale 38.613
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 13.171
SG - Singapore 3.546
CN - Cina 3.229
VN - Vietnam 3.154
IT - Italia 2.857
GB - Regno Unito 2.035
DE - Germania 1.542
HK - Hong Kong 1.192
SE - Svezia 845
IN - India 585
FR - Francia 573
BR - Brasile 552
RU - Federazione Russa 449
UA - Ucraina 373
NL - Olanda 359
KR - Corea 332
IE - Irlanda 314
CI - Costa d'Avorio 283
JP - Giappone 283
BD - Bangladesh 261
FI - Finlandia 217
TG - Togo 213
ZA - Sudafrica 167
CA - Canada 154
EE - Estonia 107
PH - Filippine 94
AT - Austria 90
ID - Indonesia 85
AR - Argentina 82
JO - Giordania 82
BE - Belgio 81
TH - Thailandia 73
TR - Turchia 69
PL - Polonia 66
BG - Bulgaria 61
CH - Svizzera 58
ES - Italia 58
MX - Messico 55
IQ - Iraq 45
TW - Taiwan 43
NG - Nigeria 37
AU - Australia 36
PT - Portogallo 35
SA - Arabia Saudita 34
PK - Pakistan 33
SC - Seychelles 32
HR - Croazia 29
UZ - Uzbekistan 28
GR - Grecia 27
CO - Colombia 26
EC - Ecuador 24
IR - Iran 20
LT - Lituania 20
RO - Romania 19
MA - Marocco 18
VE - Venezuela 18
CL - Cile 16
IL - Israele 15
KE - Kenya 15
MY - Malesia 15
PE - Perù 14
CZ - Repubblica Ceca 13
PY - Paraguay 12
DK - Danimarca 11
EG - Egitto 11
LB - Libano 11
TN - Tunisia 11
AE - Emirati Arabi Uniti 10
NZ - Nuova Zelanda 10
SK - Slovacchia (Repubblica Slovacca) 8
JM - Giamaica 7
SY - Repubblica araba siriana 7
KZ - Kazakistan 6
RS - Serbia 6
SI - Slovenia 6
UY - Uruguay 6
DZ - Algeria 5
GH - Ghana 5
HU - Ungheria 5
NP - Nepal 5
SM - San Marino 5
AL - Albania 4
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
ET - Etiopia 4
MT - Malta 4
OM - Oman 4
XK - ???statistics.table.value.countryCode.XK??? 4
CR - Costa Rica 3
CY - Cipro 3
GT - Guatemala 3
HN - Honduras 3
KH - Cambogia 3
LK - Sri Lanka 3
LY - Libia 3
PA - Panama 3
PS - Palestinian Territory 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
Totale 38.568
Salva come PNG Salva come JPEG
Città #
Singapore 2.442
Southend 1.694
Ashburn 1.553
Hong Kong 1.102
Fairfield 914
Chandler 901
San Jose 834
Ho Chi Minh City 737
Hefei 728
Santa Clara 689
Dong Ket 595
Hanoi 552
Bologna 536
Wilmington 460
Frankfurt am Main 452
Princeton 417
Woodbridge 407
Houston 389
Seattle 389
Beijing 382
Ann Arbor 362
Boardman 332
Los Angeles 306
Seoul 306
Dublin 303
Cambridge 296
Abidjan 283
Dallas 245
Tokyo 220
Lauterbourg 218
Council Bluffs 213
Lomé 213
Jacksonville 207
Milan 194
Helsinki 179
Rome 175
New York 172
Westminster 146
Nanjing 143
Padova 127
Buffalo 124
Berlin 120
Redmond 114
São Paulo 99
Turin 90
Da Nang 86
Saint Petersburg 84
Shenyang 82
Amman 81
Redondo Beach 81
Haiphong 80
Bremen 79
Jinan 78
Medford 78
Shanghai 77
London 74
Bengaluru 69
Brussels 69
Florence 67
San Diego 67
The Dalles 63
Munich 59
Orem 59
Mülheim 57
Sofia 56
Chicago 55
Guangzhou 55
Jakarta 54
Toronto 52
Falkenstein 50
Vienna 50
Nanchang 48
Phoenix 48
Falls Church 47
Hebei 47
Nuremberg 44
Zhengzhou 42
San Francisco 41
Warsaw 41
Amsterdam 40
Changsha 40
Bern 39
Dearborn 39
Tianjin 38
Biên Hòa 37
Biella 36
Des Moines 36
Modena 35
Bangkok 34
Jiaxing 33
Secaucus 33
Hangzhou 32
Istanbul 32
Redwood City 31
Abeokuta 30
Olalla 30
Palermo 30
Yubileyny 30
Brooklyn 29
Johannesburg 29
Totale 24.193
Salva come PNG Salva come JPEG
Nome #
'Use of antipsychotics in children and adolescents: A picture from the ARITMO population-based European cohort study' 776
Leucoencefalopatia Multifocale Progressiva: complicanza dell'immunosoppressione o reazione avversa da farmaci? 605
Torsadogenic risk of antipsychotics: combining adverse event reports with drug utilization data across Europe. 492
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance 491
ROCCA cohort study: Nationwide results on safety of Gam-COVID-Vac vaccine (Sputnik V) in the Republic of San Marino using active surveillance 367
Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems 342
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage 313
Modified-Chronic Disease Score (M-CDS): Predicting the individual risk of death using drug prescriptions 308
Adopting STOPP/START Criteria Version 3 in Clinical Practice: A Q&A Guide for Healthcare Professionals 307
Antibiotic use varies substantially among adults: a cross-national study from five European Countries in the ARITMO project 304
Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS) 303
Farmacoutilizzazione in ospedale: analisi delle variabilità in una realtà regionale 290
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the ‘impulse control disorders’ diagnostic construct 289
Biomarkers of Kidney Injury in Very-low-birth-weight Preterm Infants: Influence of Maternal and Neonatal Factors 286
Adverse Events to Food Supplements Containing Red Yeast Rice: Comparative Analysis of FAERS and CAERS Reporting Systems 277
Adverse cardiovascular events associated with triptans and ergotamines for treatment of migraine: Systematic review of observational studies 272
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System 269
Appropriateness of Proton Pump Inhibitor (PPI) prescription in patients admitted to hospital: Attitudes of general practitioners and hospital physicians in Italy 262
Switching among Equivalents in Chronic Cardiovascular Therapies: 'Real World' Data from Italy 247
Adverse pregnancy outcomes in women exposed to gabapentin and pregabalin: data from a population-based study 247
Antipsychotics and Torsadogenic Risk: Signals Emerging from the US FDA Adverse Event Reporting System Database. 242
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System 238
Drug-Induced Renal Damage in Preterm Neonates: State of the Art and Methods for Early Detection 237
Pattern of drug use among preterm neonates: Results from an Italian neonatal intensive care unit 234
Amyotrophic Lateral Sclerosis as an Adverse Drug Reaction: A Disproportionality Analysis of the Food and Drug Administration Adverse Event Reporting System 229
A 3 year survey on the use of antibacterial agents in five Italian hospitals. 228
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System 227
Emilia-Romagna Study on Pregnancy and Exposure to Antiepileptic drugs (ESPEA): a population-based study on prescription patterns, pregnancy outcomes and fetal health 227
Risk of hospitalization from drug-drug interactions in the Elderly: real-world evidence in a large administrative database 224
Antibacterial macrolides: a drug class with a complex pharmacological profile 220
Predictors of antipsychotic prescription in a Northern Italian District (Bologna) 218
Adrenal Insufficiency with Anticancer Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor: Analysis of the FDA Adverse Event Reporting System 215
Adherence to chronic cardiovascular therapies: persistence over the years and dose coverage. 215
Prescriptions of antidepressants in primary care in Italy: pattern of use after admission of selective serotonin reuptake inhibitors for reimbursement 214
Adherence to statin therapy and patients' cardiovascular risk: a pharmacoepidemiological study in Italy 214
Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry 212
Antimicrobials and the Risk of Torsades de Pointes. The Contribution from Data Mining of the US FDA Adverse Event Reporting System 211
Multiple sclerosis as an adverse drug reaction: clues from the FDA Adverse Event Reporting System 208
Long-acting injectable antipsychotics: Six-month follow-up of new outpatient treatments in Bologna Community Mental Health Centres 207
Association between Paraesthesia and Local Anesthetics: Data Mining of the Public Version of the FDA Adverse Event Reporting System, 204
Use of antidepressants and the risk of Parkinson's disease in the Local Health Trust of Bologna: A historical cohort study 202
Use of phytoestrogens and effects perceived by postmenopausal women: result of a questionnaire-based survey 199
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS 198
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System 197
Deprescribing as a strategy for improving safety of medicines in older people: Clinical and regulatory perspective 196
Assessing liver injury associated with antimycotics: Concise literature review and clues from data mining of the FAERS database 196
Social and clinical descriptors of antipsychotic prescription 196
Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project. 196
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems 196
Time to Treatment Intensification in Patients Receiving DPP4 Inhibitors Versus Sulfonylureas as the First Add-On to Metformin Monotherapy: A Retrospective Cohort Study 194
Myocarditis and pericarditis after immunization: Gaining insights through the Vaccine Adverse Event Reporting System 194
Cardiovascular, Ocular and Bone Adverse Reactions Associated with Thiazolidinediones: A Disproportionality Analysis of the US FDA Adverse Event Reporting System Database. 192
Triptans and serious adverse vascular events: Data mining of the FDA Adverse Event Reporting System database 192
The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project 192
An approach to evaluate appropriateness in the antibacterial therapy in Italian hospitals. 190
Prescription patterns of antiepileptic drugs in young women: development of a tool to distinguish between epilepsy and psychiatric disorders 190
Drug-induced Kounis syndrome: A matter of pharmacovigilance 189
An update on the first decade of the European centralized procedure: how many innovative drugs? 188
Human papillomavirus vaccine and demyelinating diseases-A systematic review and meta-analysis 188
Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. 187
Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study 185
Clinically important drug-drug interactions in poly-treated elderly outpatients: A campaign to improve appropriateness in general practice 185
Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping 184
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment 183
Comparing the Prevalence of Polypharmacy and Potential Drug-Drug Interactions in Nursing Homes and in the Community Dwelling Elderly of Emilia Romagna Region 183
Strategies and Tools for Supporting the Appropriateness of Drug Use in Older People 182
Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics 182
Disproportionality signal of progressive multifocal leukoencephalopathy: monoclonal antibodies versus other immunosuppressants 182
Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting 182
Drug-induced renal injury in neonates: challenges in clinical practice and perspectives in drug development 182
Hepatitis B vaccination and the putative risk of central demyelinating diseases - A systematic review and meta-analysis 180
Pro-arrhythmic potential of oral antihistamines (H1): Combining adverse event reports with drug utilization data across Europe 180
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 178
Prevalence and determinants of long-term utilization of antidepressant drugs: A retrospective cohort study 178
Evaluating sacubitril/valsartan as a treatment option for heart failure with reduced ejection fraction and preserved ejection fraction 177
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study 175
Comparison of drug prescribing before and during the COVID-19 pandemic: A cross-national European study 174
Changes in prevalence and pattern of drug use in a ten years period in Italy. 8th Congress of the European Association for Clinical Pharmacology and Therapeutics 174
Liver injury with drugs used for multiple sclerosis: A contemporary analysis of the FDA Adverse Event Reporting System 174
Dapagliflozin and cardiovascular outcomes: anything else to DECLARE? 173
QT interval shortening in spontaneous reports submitted to the FDA: the need for consensus 172
The hERG K+ channel: target and antitarget strategies in drug development. 171
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement 170
Assessing the environmental impact of medicines in Italy using data from the Italian Medicines Agency 170
The interface of depression and diabetes: treatment considerations 169
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies 169
Paraesthesia after Local Anaesthetics: An Analysis of Reports to the FDA Adverse Event Reporting System 169
Antibiotic Use and Risk of Multiple Sclerosis: A Nested Case-Control Study in Emilia-Romagna Region, Italy 169
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance 165
Antimicrobial-induced torsades de pointes: towards risk stratification by data mining of the FDA Adverse Event Reporting System. 164
La condivisione dei trattamenti farmacologici in psichiatria e la percezione degli effetti avversi ai farmaci antipisicotici da medico, paziente e familiare 163
Predictors of non-adherence with oral bisphosphonates: an Italian retrospective cohort study on administrative databases 162
Recurrence of pericarditis after influenza vaccination: a case report and review of the literature 162
Impact of the COVID-19 Pandemic on the Therapeutic Continuity among Outpatients with Chronic Cardiovascular Therapies 161
Safety of COVID-19 Vaccines Among the Paediatric Population: Analysis of the European Surveillance Systems and Pivotal Clinical Trials 161
Farmaci lassativi e purganti 161
Excipients in medicinal products used in gastroenterology as a possible cause of side effects. 159
Fattori determinanti nell'utilizzo dei farmaci antipsicotici 158
Use and Perception of Phytoestrogens in Postmenopausal Women: Result of a Questionnaire-Based Survey 157
Developing a Method To Identify Prescribing Profiles of Antihypertensive Drugs in General Practice. 156
Totale 22.224
Salva come PNG Salva come JPEG
Categoria #
all - tutte 106.682
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 346
Totale 107.028
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021873 0 0 0 0 0 0 0 0 0 0 0 873
2021/20223.831 401 121 201 192 318 226 160 267 169 229 919 628
2022/20234.598 505 599 350 549 276 322 171 304 725 189 385 223
2023/20242.067 123 226 227 297 161 209 88 344 46 133 127 86
2024/20256.024 379 780 562 367 933 372 376 259 141 375 313 1.167
2025/202614.979 1.153 1.361 1.309 906 1.512 1.096 2.101 484 2.370 1.192 818 677
Totale 39.440